Literature DB >> 1982894

Transdermal administration of the dopamine agonist N-0437 and seven ester prodrugs: comparison with oral administration in the 6-OHDA turning model.

I den Daas1, P G Tepper, H Rollema, A S Horn.   

Abstract

The potent and selective D2-agonist N-0437 [2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin] undergoes considerable first-pass metabolism after oral administration due to glucuronidation of the phenolic group. In an attempt to improve its bioavailability, seven ester prodrugs of N-0437 were synthesized, i.e. the acetyl-, propionyl-, isobutyryl-, pivaloyl-, 2-amino-phenyl-, 2-methoxy-phenyl- and 2,4-dimethylphenyl-analogues. In vivo activities were assessed by measuring contralateral turning after transdermal administration of N-0437 and its prodrugs to rats with unilateral 6-OHDA lesions of the nigrostriatal pathway. From time-effect curves the area under the curve for separate time intervals was taken as a measure of dopaminergic activity during that interval. It was found that slowly hydrolyzing prodrugs, which are known to show an improved duration of action after oral administration, are devoid of activity after transdermal application. The acetyl-, the propionyl- and the isobutyryl analogues, which are prodrugs with a relatively high hydrolysis rate, were found to have interesting and promising profiles following transdermal application.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1982894     DOI: 10.1007/bf00175708

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  12 in total

1.  Early dopamine agonist therapy in Parkinson's disease.

Authors:  U K Rinne
Journal:  Mov Disord       Date:  1989       Impact factor: 10.338

2.  Stereoselective reversal of MPTP-induced parkinsonism in the marmoset after dermal application of N-0437.

Authors:  P A Löschmann; P N Chong; M Nomoto; P G Tepper; A S Horn; P Jenner; C D Marsden
Journal:  Eur J Pharmacol       Date:  1989-08-03       Impact factor: 4.432

3.  Antiparkinsonian efficacy of a novel transdermal delivery system for (+)-PHNO in MPTP-treated squirrel monkeys.

Authors:  N M Rupniak; S J Tye; C A Jennings; A E Loper; J V Bondi; M Hichens; E Hand; S D Iversen; S M Stahl
Journal:  Neurology       Date:  1989-03       Impact factor: 9.910

4.  Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies.

Authors:  M M Mouradian; J L Juncos; G Fabbrini; T N Chase
Journal:  Ann Neurol       Date:  1987-10       Impact factor: 10.422

5.  Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system.

Authors:  U Ungerstedt; G W Arbuthnott
Journal:  Brain Res       Date:  1970-12-18       Impact factor: 3.252

Review 6.  [Drugs and the body (VI)--Transdermal therapeutic systems].

Authors:  P Pflegel; M Dittgen
Journal:  Pharmazie       Date:  1987-12       Impact factor: 1.267

7.  The antiparkinsonian actions and pharmacokinetics of transdermal (+)-4-propyl-9-hydroxynaphthoxazine (+PHNO): preliminary results.

Authors:  R J Coleman; K W Lange; N P Quinn; A E Loper; J V Bondi; M Hichens; S M Stahl; C D Marsden
Journal:  Mov Disord       Date:  1989       Impact factor: 10.338

8.  In vitro binding of the very potent and selective D-2 dopamine agonist, [3H]N-0437 to calf caudate membranes.

Authors:  J Van der Weide; J B De Vries; P G Tepper; A S Horn
Journal:  Eur J Pharmacol       Date:  1987-02-10       Impact factor: 4.432

9.  The metabolic fate of the dopamine agonist 2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin in rats after intravenous and oral administration. II. Isolation and identification of metabolites.

Authors:  T K Gerding; B F Drenth; R A de Zeeuw; P G Tepper; A S Horn
Journal:  Xenobiotica       Date:  1990-05       Impact factor: 1.908

10.  Improvement of the oral bioavailability of the selective dopamine agonist N-0437 in rats: the in vitro and in vivo activity of eight ester prodrugs.

Authors:  I den Daas; P G Tepper; A S Horn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-03       Impact factor: 3.000

View more
  2 in total

Review 1.  Continuous drug delivery in early- and late-stage Parkinson's disease as a strategy for avoiding dyskinesia induction and expression.

Authors:  P Jenner; A C McCreary; D K A Scheller
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

Review 2.  Antiparkinson prodrugs.

Authors:  Antonio Di Stefano; Piera Sozio; Laura Serafina Cerasa
Journal:  Molecules       Date:  2008-01-16       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.